Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify
Animals
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Line, Tumor
Cell Proliferation
Enzyme Activation
ErbB Receptors
/ antagonists & inhibitors
Genotype
Humans
Lung Neoplasms
/ drug therapy
Mice
Mitogen-Activated Protein Kinase Kinases
/ metabolism
Mutation
/ genetics
Phosphatidylinositol 3-Kinases
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Proto-Oncogene Proteins p21(ras)
/ genetics
Receptor Protein-Tyrosine Kinases
/ metabolism
Signal Transduction
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
28
05
2018
revised:
19
07
2018
accepted:
10
07
2019
pubmed:
20
7
2019
medline:
10
6
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
Most non-small cell lung cancers (NSCLC) contain nontargetable mutations, including
Identifiants
pubmed: 31320402
pii: 1535-7163.MCT-18-0573
doi: 10.1158/1535-7163.MCT-18-0573
doi:
Substances chimiques
KRAS protein, human
0
ErbB Receptors
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1863-1874Informations de copyright
©2019 American Association for Cancer Research.